title: Prediction of response to neoadjuvant chemotherapy in breast cancer patients by circulating apoptotic biomarkers nucleosomes, DNAse, cytokeratin-18 fragments and survivin.
abstract: Biomarkers predicting response to neoadjuvant chemotherapy in locally confined breast cancer (LBC) are highly needed. We prospectively assessed serial blood levels of apoptotic biomarkers nucleosomes, DNAse activity, cytokeratin-18 fragments (M30) and survivin in 51 LBC patients and correlated them with response to neoadjuvant treatment and established tumor markers. As controls, we used 31 healthy subjects, 13 patients with benign diseases and 28 with metastatic breast cancer (MBC). Levels of nucleosomes and survivin were elevated in LBC and MBC while M30, CEA and CA 15-3 levels were only elevated in MBC. During neoadjuvant chemotherapy, LBC patients with no change of disease (N=13) had significantly higher pretherapeutic levels of nucleosomes than patients with remission (N=38). We conclude that apoptotic biomarkers bear valuable information for diagnosis and therapy response prediction in LBC patients.
authors.affiliation: Haematology and Oncology Outpatient Cancer Care Center, Franz-Schrank-Str. 2, 80638 Munich, Germany.
authors.forename: Oliver J
authors.initials: OJ
authors.lastname: Stoetzer
authors.forename: Debora M I
authors.initials: DM
authors.lastname: Fersching
authors.forename: Christoph
authors.initials: C
authors.lastname: Salat
authors.forename: Oliver
authors.initials: O
authors.lastname: Steinkohl
authors.forename: Christian J
authors.initials: CJ
authors.lastname: Gabka
authors.forename: Ulrich
authors.initials: U
authors.lastname: Hamann
authors.forename: Michael
authors.initials: M
authors.lastname: Braun
authors.forename: Axel-Mario
authors.initials: AM
authors.lastname: Feller
authors.forename: Volker
authors.initials: V
authors.lastname: Heinemann
authors.forename: Barbara
authors.initials: B
authors.lastname: Siegele
authors.forename: Dorothea
authors.initials: D
authors.lastname: Nagel
authors.forename: Stefan
authors.initials: S
authors.lastname: Holdenrieder
mesh_terms: D000328:Adult; D000368:Aged; D017209:Apoptosis; D014408:Biomarkers, Tumor / Q000097:blood; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D002272:Carcinoembryonic Antigen / Q000097:blood; D003851:Deoxyribonucleases / Q000378:metabolism*; D005260:Female; D006801:Humans; D051034:Inhibitor of Apoptosis Proteins / Q000097:blood*; D053538:Keratin-18 / Q000097:blood*; D008875:Middle Aged; D018396:Mucin-1 / Q000097:blood; D020360:Neoadjuvant Therapy / Q000379:methods*; D009707:Nucleosomes / Q000378:metabolism*; D012680:Sensitivity and Specificity; D000077022:Survivin
chemical_list: C107489:BIRC5 protein, human; D014408:Biomarkers, Tumor; D002272:Carcinoembryonic Antigen; D051034:Inhibitor of Apoptosis Proteins; D053538:Keratin-18; D018396:Mucin-1; D009707:Nucleosomes; D000077022:Survivin; D003851:Deoxyribonucleases